The Verdict Recursion Pharmaceuticals offers a compelling investment for exposure to AI-driven drug discovery, backed by a strong balance sheet.

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part ...

AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles.